Clinical Trial Update: Liposomal Tretinoin in Treating Patients With Recurrent or Refractory Hodgkin's Disease [Phase 2]

View source ↗

Summary

A Phase 2 trial of liposomal tretinoin for recurrent or refractory Hodgkin lymphoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• liposomal tretinoin (liposomal all-trans retinoic acid)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lymphoma | Phase 2 | Status: WITHDRAWN